CN113755515A - Recombinant escherichia coli for efficiently producing clavulanic acid and application thereof - Google Patents
Recombinant escherichia coli for efficiently producing clavulanic acid and application thereof Download PDFInfo
- Publication number
- CN113755515A CN113755515A CN202111151501.6A CN202111151501A CN113755515A CN 113755515 A CN113755515 A CN 113755515A CN 202111151501 A CN202111151501 A CN 202111151501A CN 113755515 A CN113755515 A CN 113755515A
- Authority
- CN
- China
- Prior art keywords
- escherichia coli
- recombinant escherichia
- fermentation
- clavulanic acid
- lon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 54
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 title claims abstract description 44
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 title claims abstract description 44
- 229960003324 clavulanic acid Drugs 0.000 title claims abstract description 44
- 238000000855 fermentation Methods 0.000 claims abstract description 51
- 230000004151 fermentation Effects 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 37
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 43
- 238000004519 manufacturing process Methods 0.000 claims description 43
- 239000008103 glucose Substances 0.000 claims description 41
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 40
- 101150043276 Lon gene Proteins 0.000 claims description 32
- 101100235786 Rattus norvegicus Lonp1 gene Proteins 0.000 claims description 27
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 26
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 26
- 229920001282 polysaccharide Polymers 0.000 claims description 26
- 150000004676 glycans Chemical class 0.000 claims description 24
- 239000005017 polysaccharide Substances 0.000 claims description 24
- 230000015572 biosynthetic process Effects 0.000 claims description 22
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 20
- 239000011780 sodium chloride Substances 0.000 claims description 20
- 101150117960 rcsA gene Proteins 0.000 claims description 16
- 238000003786 synthesis reaction Methods 0.000 claims description 14
- 101150041954 galU gene Proteins 0.000 claims description 13
- 101150096208 gtaB gene Proteins 0.000 claims description 13
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 10
- 239000001110 calcium chloride Substances 0.000 claims description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 9
- 239000002158 endotoxin Substances 0.000 claims description 9
- 108091008053 gene clusters Proteins 0.000 claims description 9
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 101100194532 Escherichia coli (strain K12) rfaG gene Proteins 0.000 claims description 7
- 101100540702 Escherichia coli (strain K12) waaU gene Proteins 0.000 claims description 7
- 101150030372 rfaB gene Proteins 0.000 claims description 7
- 101150068793 rfaP gene Proteins 0.000 claims description 7
- 101150012219 rfaQ gene Proteins 0.000 claims description 7
- 101150033672 rfaY gene Proteins 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 108010082433 UDP-glucose-hexose-1-phosphate uridylyltransferase Proteins 0.000 claims description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 claims description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 230000004568 DNA-binding Effects 0.000 claims 1
- 239000001963 growth medium Substances 0.000 abstract description 19
- 239000007787 solid Substances 0.000 abstract description 16
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 230000004044 response Effects 0.000 abstract description 9
- 230000001976 improved effect Effects 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 239000000243 solution Substances 0.000 description 29
- 239000013612 plasmid Substances 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 20
- 101150065066 hns gene Proteins 0.000 description 18
- 239000012634 fragment Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 239000007864 aqueous solution Substances 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 238000010276 construction Methods 0.000 description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 238000005457 optimization Methods 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 229920002444 Exopolysaccharide Polymers 0.000 description 11
- 238000001444 catalytic combustion detection Methods 0.000 description 11
- 238000013461 design Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 108091033409 CRISPR Proteins 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 101150041296 rfaF gene Proteins 0.000 description 8
- -1 waaZ Proteins 0.000 description 8
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 7
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 238000013401 experimental design Methods 0.000 description 7
- 150000002772 monosaccharides Chemical class 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 6
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 239000007836 KH2PO4 Substances 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000002296 dynamic light scattering Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 101150057996 rfaL gene Proteins 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- 238000010354 CRISPR gene editing Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 4
- 239000001888 Peptone Substances 0.000 description 4
- 108010080698 Peptones Proteins 0.000 description 4
- 102000018120 Recombinases Human genes 0.000 description 4
- 108010091086 Recombinases Proteins 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000009477 glass transition Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 235000019319 peptone Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 241000660147 Escherichia coli str. K-12 substr. MG1655 Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002983 circular dichroism Methods 0.000 description 3
- 230000009194 climbing Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000001595 flow curve Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 238000012224 gene deletion Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000013028 medium composition Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 125000001477 organic nitrogen group Chemical group 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000000518 rheometry Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000000089 atomic force micrograph Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 2
- 238000001142 circular dichroism spectrum Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229950006191 gluconic acid Drugs 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229960000268 spectinomycin Drugs 0.000 description 2
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000003190 viscoelastic substance Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 102000007566 ATP-Dependent Proteases Human genes 0.000 description 1
- 108010071550 ATP-Dependent Proteases Proteins 0.000 description 1
- 101500000959 Bacillus anthracis Protective antigen PA-20 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 101100412041 Escherichia coli (strain K12) rcsD gene Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001201 calcium accumulation Effects 0.000 description 1
- 238000007707 calorimetry Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000668 effect on calcium Effects 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000002386 heptoses Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 101150062750 igaA gene Proteins 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 238000012269 metabolic engineering Methods 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 101150031509 rcsB gene Proteins 0.000 description 1
- 101150094078 rcsC gene Proteins 0.000 description 1
- 101150042337 rcsF gene Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1022—Transferases (2.) transferring aldehyde or ketonic groups (2.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07009—UTP-glucose-1-phosphate uridylyltransferase (2.7.7.9), i.e. UDP-glucose-pyrophosphorylase
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses recombinant escherichia coli for efficiently producing clavulanic acid and application thereof, and belongs to the fields of genetic engineering, fermentation engineering and material science. According to the invention, by editing key genes synthesized by CA, a mutant for overproducing CA is constructed; then obtaining an optimal culture medium by a single factor and response surface method, and optimizing the fermentation conditions in the fermentation tank. The yield of CA prepared by the method reaches 19.79g/L, which is higher than the known maximum yield (10.39g/L), and is improved by 90.47%. In addition, the CA prepared by the method is characterized in properties, and the CA is proved to have excellent properties such as solid form, molecular weight, space structure, chain conformation, thermal and rheological properties and the like. The high yield of CA in the invention provides a tamping foundation for large-scale production and research on CA properties, and the disclosure of CA properties provides a solid theoretical foundation for the development and utilization of CA.
Description
Technical Field
The invention relates to recombinant escherichia coli for efficiently producing clavulanic acid and application thereof, belonging to the fields of genetic engineering, fermentation engineering and material science.
Background
Natural polysaccharides, particularly polysaccharides having triple helix conformation, have unique properties and functions such as anti-tumor, immunomodulation, etc., and are receiving increasing attention in the fields of food and medicine. Therefore, the research and development of the polysaccharide have important significance in the field of high molecules. Claritanic Acid (CA) is an extracellular protective barrier polysaccharide widely existing in intestinal bacteria, and plays a crucial role in adaptation of thalli to external environment. CA in Escherichia coli K-12 strain MG1655, is composed of D-galactose, L-fucose, D-gluconic acid and D-glucose composed of repeating unit. It has been reported that the intestinal microorganisms produce CA to prolong the life of the host, thereby indicating that CA has a function of delaying aging. In addition, the high content of L-fucose (about 30%) in CA means that CA has great application potential in the aspects of anti-inflammation, anti-tumor, anti-cancer, immunity enhancement and the like. Meanwhile, the CA modified cellulose hydrogel has excellent water-retaining property, so that the CA modified cellulose hydrogel becomes an excellent choice in the cosmetic and healthcare industries.
Under extreme environmental or envelope stress conditions, E.coli can synthesize CA. In our previous work, we found that truncation of Lipopolysaccharide (LPS) could better promote CA synthesis. In addition, CA biosynthesis is regulated by the Rcs phosphate delivery system, which includes six genes, igaA, rcsF, rcsC, rcsD, rcsB, and rcsA. Among them, RcsA can activate the CA gene cluster and exert a positive regulatory effect in CA synthesis. However, RcsA can be hydrolyzed by the ATP-dependent protease Lon (encoded by the Lon gene), and therefore, the half-life of RcsA is short; furthermore, rcsA can also be silenced by histone HNS (encoded by the HNS gene) (fig. 1).
CA has a wide development prospect in multiple application fields, and the research and application of CA are promoted more widely by improving CA yield and revealing CA property. The highest yield of CA is reported to be 10.39g/L with a conversion of about 52% (see Wu, H., Chen, S., Ji, M., Chen, Q., Shi, J., & Sun, J. (2019.) the Activation of the hydrolytic acid biosynthesis linked to heterologous expression of the hydrolytic pathway in Escherichia coli. int J Biol Macromol,128, 752-. In addition, there is currently little research on CA properties, and most focus on monosaccharide composition, molecular weight, and rheological properties. Thus, obtaining a process that can produce Clavulanic Acid (CA) in high yields would facilitate widespread use of CA in industry.
Disclosure of Invention
In order to maximize the yield of clavulanic acid, the present invention first constructs a CA overproducing mutant by editing a key gene for CA synthesis. Then, an optimal culture medium is obtained by a single factor and response surface method, and fermentation conditions in a fermentation tank are optimized. The yield of CA prepared by the method reaches 19.79g/L, which is higher than the known maximum yield (10.39g/L), and is improved by 90.47%. In addition, the CA prepared by the method is characterized in properties, and the CA is proved to have excellent properties such as solid form, molecular weight, space structure, chain conformation, thermal and rheological properties and the like. The high yield of CA in the invention provides a tamping foundation for large-scale production and research on CA properties, and the disclosure of CA properties provides a solid theoretical foundation for the development and utilization of CA.
The invention provides a method for improving the yield of clavulanic acid, which is to knock out and express key genes on an escherichia coli genome to obtain a high-yield clavulanic acid strain.
The invention provides a recombinant escherichia coli, wherein a lipopolysaccharide core polysaccharide synthesis gene cluster waaL, waaU, waaZ, waaY, waaR, waaO, waaB, waaP, waaG and waaQ on a genome are knocked out, escherichia coli with a Lon protein coding gene Lon and an HNS regulatory protein coding gene HNS knocked out is taken as a host cell, and a UTP-1-phosphoglucose uridyltransferase coding gene galU and a DNA combined transcription activator RcsA coding gene rcsA are overexpressed.
In one embodiment of the invention, the lipopolysaccharide core polysaccharide synthesis gene clusters waaL, waaU, waaZ, waaY, waaR, waaO, waaB, waaP, waaG, waaQ, have NCBI accession numbers 948148, 948147, 948146, 948145, 948142, 948143, 948144, 948150, 948149, 94815; the NCBI accession number for lon is 945085; the NCBI accession number of hns is 945829; the NCBI accession number of galU is 945730; the NCBI accession number for rcsA is 946467.
In one embodiment of the invention, the recombinant Escherichia coli takes Escherichia coli str.K-12MG1655 as a host cell and pRSFDuet-1 as an expression vector.
In one embodiment of the invention, the recombinant E.coli is P20The strong promoter strengthens the expression of galU and rcsA genes; the P is20The nucleotide sequence of the strong promoter is: AATACTTGACATATCACTGTGATTCACATATAATATGCG are provided.
In one embodiment of the present invention, the recombinant escherichia coli is constructed by the following method:
(1) construction of host cells:
knocking out lipopolysaccharide core polysaccharide synthesis gene clusters waaL, waaU, waaZ, waaY, waaR, waaO, waaB, waaP, waaG and waaQ on the genome of an Escherichia coli str.K-12MG1655 host cell, and knocking out lon and hns genes at the same time to construct the host cell;
(2) construction of recombinant vectors:
using the promoter P20After being respectively connected with key genes galU and rcsA in a CA biosynthesis pathway, the recombinant expression vector is connected with an expression vector pRSFDuet-1 to prepare a recombinant vector;
(3) construction of recombinant E.coli:
and (3) introducing the recombinant vector prepared in the step (2) into the host cell prepared in the step (1) to obtain recombinant escherichia coli.
The invention also provides a method for producing the clavulanic acid by fermenting glucose, which comprises the following steps: the recombinant escherichia coli is prepared by fermentation.
In one embodiment of the invention, the seed solution of the recombinant escherichia coli is inoculated into a fermentation medium and fermented to prepare the clavulanic acid, wherein the fermentation medium comprises: 15-30 g/L glucose, 35-45 g/L Na2HPO4·12H2O,1~8g/L NH4Cl,2~4g/L KH2PO4,2~4g/L NaCl,0.01~0.05g/L CaCl2And 0.1-0.5 g/L MgSO4。
In one embodiment of the invention, the fermentation medium comprises: 21.47g/L glucose, 40.2g/L Na2HPO4·12H2O,1g/L NH4Cl,3g/L KH2PO4,3g/L NaCl,0.014g/L CaCl2And 0.24g/L MgSO4。
In one embodiment of the invention, the seed solution of the recombinant Escherichia coli is inoculated in a fermentation medium in an amount OD6000.04 to 0.21.
In one embodiment of the invention, the seed solution of the recombinant escherichia coli is inoculated into a fermentation medium, and the fermentation conditions are as follows: at 25-37 deg.C and 150-250 rpm.
In one embodiment of the present invention, the preparation method of the seed liquid comprises: adding the recombinant escherichia coli into an LB liquid culture medium, and culturing for 12-16 h at 35-38 ℃ and 150-250 rpm.
In one embodiment of the invention, the pH is controlled to be not less than 6.0 and the dissolved oxygen is controlled to be not less than 30% during the fermentation process of the clavulanic acid, and the inoculation amount keeps the initial bacterial density OD6000.04 to 0.21.
The invention also provides the clavulanic acid prepared by the method.
In one embodiment of the present invention, analyzing the physical properties of the prepared clavulanic acid comprises: solid form, molecular weight, molecular conformation, thermal properties, and rheology.
In one embodiment of the invention, the clavulanic acid solid obtained by the process is in the form of a paper crumb.
In one embodiment of the invention, the clavulanic acid obtained by the process has a molecular weight of 2.0X 106~4.85×106And D, dalton.
In one embodiment of the invention, the clavulanic acid obtained by the method has a spherical chain conformation in an aqueous solution, and the molecular diameter is 222.7-286.4 nanometers.
In one embodiment of the invention, the clavulanic acid obtained by the method is stable within 30-102 ℃, and the glass transition temperature, the melting temperature and the decomposition temperature are 123.5 ℃, 253.9 ℃ and 291.9 ℃ respectively.
In one embodiment of the invention, the aqueous solution of clavulanic acid obtained by the process is a non-newtonian fluid whose viscosity is related to concentration, shear rate, salt, temperature and pH. Exhibit viscosity and elasticity at high concentrations of clavulanic acid.
The invention also provides application of the prepared clavulanic acid in the fields of food, medicine, materials or environmental protection.
The invention also provides application of the recombinant escherichia coli in preparation of a product containing the clavulanic acid.
In one embodiment of the invention, the product is a food, pharmaceutical or chemical.
Advantageous effects
(1) The invention takes MG1655 delta (L-Q) of a gene cluster waaL, waaU, waaZ, waaY, waaR, waaO, waaB, waaP, waaG and waaQ with the knockout of lipopolysaccharide core polysaccharide synthesis genes on a genome as a host cell, knocks out lon and hns genes on the genome of the host cell to obtain a mutant strain WQM003, and the clavulanic acid yield of the WQM003 is improved by 2.43 times compared with that of the MG1655 delta (L-Q). Subsequently, a pRAU plasmid is constructed by expressing galU and rcsA genes, and the plasmid is introduced into WQM003 to obtain the recombinant strain WQM003/pRAU, and compared with the MG1655 delta (L-Q) strain, the yield of the clavulanic acid obtained by fermenting the recombinant strain WQM003/pRAU is improved by 4.24 times.
(2) The clavulanic acid production culture medium is optimized in a triangular flask through a single-factor experiment and a response surface method to obtain the optimal culture medium for clavulanic acid production, and the yield of the clavulanic acid of WQM003/pRAU reaches 12.47g/L by using the optimal culture medium for fermentation, and is 33.58 times higher than that of the starting strain MG1655 delta (L-Q).
(3) In order to expand the production of the clavulanic acid, the fermentation conditions are optimized in a fermentation tank, and through high-yield strain construction, fermentation culture medium and fermentation condition optimization, the yield of the clavulanic acid of WQM003/pRAU reaches 19.79g/L, which is 53.49 times higher than that of the original strain, and reaches the highest yield of the clavulanic acid at present.
(4) To expand the application of clavulanic acid, the physical properties of clavulanic acid were further investigated. The clavulanic acid solid is in the shape of paper scraps; molecular weight of 2.0X 106~4.85×106Dalton; the clavulanic acid is in a spherical chain conformation in an aqueous solution, and the molecular diameter is 222.7-286.4 nanometers; the clavulanic acid is stable within 30-102 ℃, and the glass transition temperature, the melting temperature and the decomposition temperature are 123.5 ℃, 253.9 ℃ and 291.9 ℃ respectively; aqueous clavulanic acid is a non-newtonian fluid whose viscosity is related to concentration, shear rate, salt, temperature and pH, exhibiting viscosity and elasticity at high concentrations of clavulanic acid.
Drawings
FIG. 1: biosynthesis and regulation of CA in Escherichia coli K-12 strain MG 1655. A is a gene and a pathway for CA biosynthesis; truncation of B, LPS, promotes CA production; c is CA biosynthesis which is regulated by RcsA, HNS and Lon proteins.
FIG. 2: starting strain and mutant strain clavulanic acid yield. A is the screening of the original strain, and B is the yield of the mutant strain clavulanic acid.
FIG. 3: and (3) constructing pRAU plasmid. The SD sequence overexpresses the rcsA and galU genes using the strong promoter P20.
FIG. 4: and E.coli cell exopolysaccharide tannin mordant dyeing.
FIG. 5: the medium for CA production was optimized for a single factor experiment based on M9 medium. A is the type of carbon source; b is the glucose concentration; c is a nitrogen source type; d isKH2PO4Concentration; e is Na2HPO4·12H2The concentration of O; f is NaCl concentration.
FIG. 6: the culture medium and fermentation process for CA production are optimized. A is pareto chart analysis designed for PB; b is the steepest climbing experiment result; c is a 2D and 3D response surface diagram; d is the influence of the inoculum size on the CA yield in the fermentation process; e, fermentation of clavulanic acid without controlling the pH value; f, controlling the pH value to be kept to be not less than 6.0, and fermenting.
FIG. 7: morphology of CA, monosaccharide composition and molecular weight. A is the solid form of visual CA; b is the solid state of CA observed by SEM; c is monosaccharide composition of CA; d is the molecular weight of CA.
FIG. 8: advanced structure and calorimetric analysis of CA. A is Congo red determination; b is CD spectrometry; c is atomic force microscope observation; d is dynamic light scattering measurement; and E is DSC measurement.
FIG. 9: effect of CA concentration, temperature, pH and salt on the shear viscosity of CA aqueous solutions. A is the influence of different CA concentrations on a CA flow curve, and the CA concentrations are 80, 60, 40, 30, 20, 10 and 1mg/mL from top to bottom; b is the influence of temperature on the CA flow curve, and the temperature range is 25-90 ℃; c is the effect of temperature on the CA flow curve; d is NaCl, KCl, CaCl2And MgCl2Effect on CA shear viscosity.
FIG. 10: viscoelastic curve of CA solution. A is the concentration of CA which is 20g/L respectively; b is the concentration of CA which is 40g/L respectively; the concentration of C is 60g/L of CA; d is the concentration of CA, and the concentration is 80g/L respectively.
Detailed Description
pTargetF, Escherichia coli str K-12MG1655 referred to in the following examples were purchased from: new England Biolabs (NEB).
The strains, culture and fermentation conditions referred to in the following examples are as follows:
table 1 describes the strains used in the present invention. Coli cells used for construction of vectors and mutants were cultured in LB medium. LB, LBG and M9 media supplemented with 18g/L agarose were used to identify CA synthesis. The CA fermentation medium consists of 15-30 g/L glucose and 35-45 g/L Na2HPO4·12H2O,1~8g/L NH4Cl,2~4g/L KH2PO4,2~4g/L NaCl,0.01~0.05g/L CaCl2And 0.1-0.5 g/L MgSO4. Kanamycin, spectinomycin, ampicillin, arabinose and isopropyl-beta-D-thiogalactopyranoside (IPTG) were at concentrations of 50mg/L, 100mg/L, 10mM and 0.5mM, respectively. To optimize CA medium, the mutants were cultured in 50mL of medium (250mL shake flasks) at 30 ℃ for 72h with shaking at 200rpm, starting OD600Is 0.02.
TABLE 1 bacterial strains and vectors used in the present invention
(2) Construction of vectors and mutants
All primers used for vector and mutant construction are listed in table 2. Deletion of hns and lon genes from MG 1655. delta. (L-Q) using the Crispr-Cas9 method produced mutant WQM 003. The upstream fragments of hns and lon were amplified with primers F1-hns/lon and R1-hns/lon, and the downstream fragments were amplified with primers F2-hns/lon and R2-hns/lon. The primers F1-hns/lon and R2-hns/lon were then used to overlap the upstream and downstream fragments to give donor DNA. pTargetF-hns/lon was amplified with primers F-sgRNA-hns/lon and R-sgRNA-hns/lon, respectively, and pTargetF-hns/lon was substituted for the original N20 sequence using pTargetF as a template, and the underlined sequence in Table 2 was the new N20 sequence. The new vector fragment was then purified by gel extraction kit and chemically transformed into E.coli DH 5a, and the correct vector was selected by sequencing with the primers T-hns/lon-F and T-sgRNA-R. Subsequently, the donor DNA and pTargetF-hns/lon were used to knock out the hns and lon genes. To construct pRSF-P20-rcsA-P20-galU by primer F-P20-rcsA-BamHI/R-rcsA-SacI and F-P20galU-SacI/R-galU-XhoI amplification of rcsA and galU genes. Thus, rcsA and gaThe lU gene has strong P20Promoter (AATACTTGACATATCACTGTGATTCACATATAATATGCG), SD sequence (AAATCAGAAGAGTATTGCTA) and underlined restriction enzyme sites in Table 2, then, amplified rcsA and galU were digested with BamHI/SacI and SacI/XhoI, and pRSFDuet-1 was digested with BamHI/XhoI. Passing the three fragments through T4DNA ligase ligation and chemical transformation into WQM003 and by primer F-P20Sequencing with-rcsA-BamHI and R-galU-XhoI selected the correct vector.
TABLE 2 primers used in the present invention
The characterization of the properties of the CA involved in the following examples is as follows:
(1) solid form of CA
Images of solid CA samples were collected by high quality camera and Scanning Electron Microscope (SEM).
(2) Monosaccharide composition of CA
To resolve the monosaccharide composition of CA, 50mg of purified CA powder was added to 7.5mL of 72% H2SO4And left at 121 ℃ for 3 h. Then, the pH of the acidolysis solution was adjusted to 7.0 and diluted appropriately so that the final concentration of CA was 50 mg/L. The samples were analysed by high pressure ion exchange chromatography using a pulsed amperometric detector and a CarboPac PA20 column (3 mm. times.150 mm). The mobile phase elution conditions were 97.4% water and 2.6% NaOH (250mM), 0min to 21 min; 92.4% -77.4% water, 2.6% NaOH (250mM) and 5% -20% NaAc (1M) from 21.1min to 30 min; 20% water and 80% NaOH (250Mm) from 30.1min to 50min at a flow rate of 0.5 mL/min.
(3) Molecular weight of CA (MW)
The MW.CA content, sample size, column temperature, mobile phase and flow rate of purified CA were measured on a Waters 1525 size exclusion chromatograph equipped with a 2410 refractive index detector (and an Ultrahydrogel Linear column) at 50g/L, 20. mu.L, 45 ℃, 0.1M NaAc, and 0.9mL/min, respectively.
(4) Congo Red assay
The congo red method identifies polysaccharides having triple-helical structures by monitoring the red shift of the maximum absorption wavelength.
A CA solution (2mL, 20g/L) was mixed with Congo red solutions (2mL, 80. mu. mol/L) prepared with NaOH of different concentrations (2mL, 80. mu. mol/L), the concentration of NaOH was from 0mol/L to 0.5mol/L, 2mL, 80. mu. mol/L Congo red solutions were prepared using NaOH solutions of concentration gradient from 0mol/L to 0.5mol/L, and 2mL, 20g/L of CA solution was mixed with the above 2mL, 80. mu. mol/L Congo red solutions. A full wavelength scan was taken of 150. mu.L of the mixture and the maximum absorption wavelength was recorded. Distilled water was used as a control instead of CA.
(5) Circular Dichroism (CD) spectrum
The CA structure was further studied on a circular dichroism spectrum (Jasco J-1700, Tokyo, Japan). The circular dichroism spectrum of the CA aqueous solution (20g/L) is measured at 25 ℃ and 190-250 nm. The results were analyzed by dichrobe circular dichroism online analysis software.
(6) Atomic Force Microscope (AFM)
The surface morphology of the CA was observed using an atomic force microscope and a commercial RTESP antimony doped silicon probe. mu.L of aqueous CA solution (20g/L) was placed on the cut mica plates and air-dried at room temperature for 12 h. Atomic force microscope images were analyzed using the NanoScope analysis 1.9 software.
(7) Dynamic Light Scattering (DLS)
To obtain the hydrodynamic radius of CA in water, dynamic light scattering was performed at 25 ℃ on an ALV/CGS-3 compact goniometer using a He-Ne laser.
(8) Differential Scanning Calorimetry (DSC)
Pyris DSC8500 with thermal analyser for the calorimetry of CA. The freeze-dried CA was placed in an aluminum pan and another empty aluminum pan served as a control, which was heated from 50 ℃ to 300 ℃ at a heating rate of 10 ℃/min and scanned under nitrogen.
(9) Rheological Properties of CA
All rheological properties of the CA were measured on a Physica-MCR302 rheometer equipped with a double-slit cup (external diameter 26.7mm, pore diameter 24.7mm, length 40mm)Amount of the compound (A). To test the effect of CA concentration on viscosity, aqueous solutions of purified CA (5, 10, 20, 30, 40, 60, and 80g/L) were prepared at various concentrations and at 25 ℃ for 1s-1To 1000s-1At a shear rate of (c). Also at 100s-1At a shear rate of 25 ℃ to 90 ℃ and a heating rate of 6 ℃/min, the viscosities of purified CA aqueous solutions of different concentrations were investigated. Effect of different pH values on CA viscosity at 25 ℃ for 1s-1To 1000s -120g/L CA in water at different pH values (5.0, 6.0, 7.0, 8.0, 9.0) were tested at shear rates of (2). The MCR302 rheometer also measures NaCl, KCl and CaCl2And MgCl2(50g/L and 100g/L) on the viscosity of a20 g/L aqueous CA solution. The shear rate at 25 ℃ is 1 to 1000s-1. Furthermore, the dynamic viscoelastic behavior at different CA concentrations (80, 60, 40, 20g/L) was performed at 15 ℃, 0.8% strain and an angular frequency range of 0.1rad/s to 100 rad/s.
The methods for identification, purification and quantitative detection of CA involved in the following examples are as follows:
the Escherichia coli cells are cultured for 48h at 30 ℃ or 37 ℃ in M9, LB and LBG solid agarose medium, then Escherichia coli single colonies are fixed, magenta staining, tannin mordant staining and methylene blue staining are sequentially carried out, the CA amount is identified under a bright field microscope, and the more blue in a field indicates that the more CA is synthesized. L-fucose is an important oligosaccharide component in CA, and the yield of CA can be calculated by detecting fucose by an improved Dische colorimetry. The CA medium (500. mu.L) was boiled for 20min to inactivate E.coli cells and to dissolve the CA polymer, and centrifuged at 12000rpm for 5min to remove E.coli cells. The supernatant (200. mu.L) was mixed with ethanol (800. mu.L) and CA was precipitated at 4 ℃ for 4 h. Then centrifuged at 12000rpm for 5min and baked at 55 ℃ for 2h to obtain a CA crude sample. CA aqueous solution (100. mu.L) and 450. mu.L of 87% H2SO4Mix and heat for 15 min. After cooling to room temperature, the absorbance of the mixture was measured at 396nm and 427nm as A396Subtract A430As a control, the name A(396-430)1. Subsequently 5.45. mu.L cysteine hydrochloride was added and the absorbance was measured again at 396nm and 430nm, A396Subtract A430Is marked as A(396-430)2(ii) a Record A(396-430)2Subtract A(396-430)1And the concentration of L-fucose was calculated using a standard curve, and the concentration of CA was derived from the level of L-fucose. In order to accurately reveal the characteristics of CA, the crude CA sample obtained in the above-mentioned method needs to be further purified by means of nuclease hydrolysis, protease hydrolysis and dialysis, and finally the purified CA is prepared by means of freeze-drying method.
The media involved in the following examples are as follows:
m9 medium: 4g/L Glucose, 17.1g/L Na2HPO4 & 12H2O, 3g/L KH2PO4, 1g/L NH4Cl, 0.24g/L MgSO4, 0.5g/L NaCl, and 0.011g/L CaCl 2.
LB medium: 5g/L yeast powder, 10g/L peptone, and 10g/L NaCl.
LBG medium: 5g/L yeast powder, 10g/L peptone, 10g/L NaCl and 4g/L glucose.
Example 1: screening of starting strains producing high yields of clavulanic acid
By knocking out the waaF gene in E.coli W3110 or the waaL-waaQ gene cluster in MG1655, CA production can be effectively promoted, resulting in truncation of LPS core polysaccharide (as shown in FIG. 1A). The invention compares the CA yield of W3110 delta waaF and MG1655 delta (L-Q), selects the strain with high CA as the initial strain to further optimize and modify. The method comprises the following specific steps:
(1) construction of MG 1655. delta. (L-Q) Strain, according to the method in SCI paper (Wang C H, Zhang H L, Wang J L, et al, analytical acid biosynthesis in Escherichia coli dependent on lipid polysaccharide structure and glucose availability, microbiological Research,2021.243.), gene knock-out was performed on Escherichia coli using CRISPR/Cas9 knock-out system, first the Escherichia coli K-12MG1655 was electroporated with pCas9 plasmid, and recombinase Gam, Bet, and Exo expression was induced by L-arabinose. The homology arm fragments (primer sequences are shown in Table 2) and pTargetF plasmid containing the specific N20 sequence were then simultaneously transfected into MG1655/pCas9 competent cells. Resistant plates were spread and cultured at 30 ℃ for 18 hours, and colonies were PCR-selected for deletion of waaL, waaU, waaZ, waaY, waaR, waaO, waaB, waaP, waaG, and waaQ genes to prepare MG 1655. delta. (L-Q) strain.
(2) Construction of W3110. DELTA.waaF Strain
According to the method in the SCI paper (Ren G, Wang Z, Li Y, et al. effects of lipopolyparaccharide core specificity on microbial acid biosynthesis pathway in Escherichia coli [ J ]. Journal of Bacteriology 2016.198: 1576. 1584.), gene deletion was performed on Escherichia coli W3110 using CRISPR/Cas9 deletion system, and pCas9 plasmid was first electroporated into Escherichia coli W3110 to induce expression of recombinases Gam, Bet, and Exo by L-arabinose. The homology arm fragments (primer sequences are shown in Table 2) and pTargetF plasmid containing the specific N20 sequence were then simultaneously electroporated into W3110/pCas9 competent cells. The resistant plate was coated and cultured at 30 ℃ for 18 hours, and then the waaF gene-deleted strain was screened by colony PCR to prepare W3110. delta. waaF strain.
The CA contents of MG 1655. delta. (L-Q) and W3110. delta. waaF were measured after fermentation for 48 hours by culturing MG 1655. delta. (L-Q) and W3110. delta. waaF in M9 medium at 30 ℃ and 200rpm, respectively (FIG. 2A), and the results were: 0.371g/L and 0.248g/L, which are respectively improved by 3.48 and 2.32 times compared with the wild type, and the yield of CA of the wild type is only 0.11 g/L. The CA production of MG 1655. delta. (L-Q) in M9 medium was higher than that of W3110. delta. waaF, indicating deletion of the waaL-waaQ gene cluster, i.e.: only two heptoses remained in the core polysaccharide, which was more effective in promoting CA synthesis (fig. 1A). Therefore, MG 1655. delta. (L-Q) was selected as a starting strain to optimize and engineer for increased CA production.
Example 2: construction of high-yield clavulanic acid strain
The activator RcsA was degraded and inhibited by Lon and HNS proteins in MG1655 Δ (L-Q) (as shown in fig. 1C). Therefore, it is necessary to knock out the lon and hns genes from the MG 1655. delta. (L-Q) genome.
The method comprises the following specific steps:
1. construction of WQM001 Strain
The lon gene on the MG1655 delta (L-Q) strain genome prepared in example 1 is knocked out, the specific method is the same as example 1, the CRISPR/Cas9 knock-out system is adopted to knock out the gene of the Escherichia coli MG1655 delta (L-Q) strain, firstly, the Escherichia coli MG1655 delta (L-Q) strain is electrically transferred into pCas9 plasmid, L-arabinose is added to induce recombinase Gam, Bet and Exo to express, and the MG1655 delta (L-Q)/pCas9 strain is obtained
Respectively amplifying an upstream homology arm and a downstream homology arm of the knockout lon gene by using an Escherichia coli MG1655 genome as a template and F1-lon/R1-lon and F2-lon/R2-lon, and then carrying out overlap PCR by using the upstream and downstream homology arms as the template and F1-lon and R2-lon primers to amplify to obtain a homology arm fragment of the knockout lon.
The plasmid ptargetF-lon was used as a template, and a linear pTargetF-lon fragment was obtained by reverse PCR amplification using F-sgRNA-lon and R-sgRNA-lon primers, and then transformed into Escherichia coli JM109 to construct a circular pTargetF-lon plasmid.
The lon-knock-out homologous arm fragment (primer sequences are shown in Table 2) and pTargetF-lon plasmid were simultaneously transfected into MG 1655. delta. (L-Q)/pCas9 competent cells. Coating a kanamycin and spectinomycin double-antibody plate, culturing at 30 ℃ for 18h, then carrying out colony PCR screening on lon gene deletion strains, and carrying out sequencing verification. The correct strain was verified and the pTargetF-lon plasmid was removed by addition of IPTG followed by overnight culture at 42 ℃ to remove the pCas9 plasmid. Finally, a mutant strain WQM001 lacking the lon gene was obtained.
2. Construction of WQM003 Strain
Knocking out hns genes on the WQM001 strain genome prepared in the step 1, specifically knocking out genes of the Escherichia coli WQM001 strain by using a CRISPR/Cas9 knocking-out system in the same way as in the example 1, firstly, electrically transferring pCas9 plasmids into the Escherichia coli WQM001 strain, and inducing recombinase Gam, Bet and Exo expression by L-arabinose.
The upstream and downstream homology arms of the hns gene were knocked out by amplifying F1-hns/R1-hns and F2-hns/R2-hns respectively using the E.coli MG1655 genome as a template. Then, the upstream and downstream homology arms were used as templates, and F1-hns and R2-hns primers were used to perform overlap PCR, thereby amplifying the fragments of homology arms from which hns genes were knocked out.
A linear pTargetF-hns fragment was obtained by reverse PCR amplification using F-sgRNA-hns and R-sgRNA-hns primers using ptargetF plasmid as a template, and transformed into a circular pTargetF-hns plasmid of Escherichia coli JM 109.
The homology arm fragment and pTargetF plasmid containing the specific N20 sequence were then simultaneously electroporated into WQM001 strain/pCas 9 competent cells. And coating a resistant plate, culturing at 30 ℃ for 18h, then carrying out colony PCR screening on hns gene deletion strains, and carrying out sequencing verification. The correct strain was verified and the pTargetF-hns plasmid was removed by addition of IPTG followed by overnight culture at 42 ℃ to remove the pCas9 plasmid. Finally, the hns gene-deleted mutant WQM003 was obtained.
3. WQM001 and WQM003 were cultured in M9 medium at 30 ℃ and 200rpm, respectively, and after fermentation for 48 hours, the CA content of WQM001 and WQM003 were measured (FIG. 2B), respectively, and the results were: 0.68g/L and 0.9g/L, the CA production of WQM001 was 1.82 times that of MG1655 Δ (L-Q), and the CA production of WQM003 was 2.43 times that of MG1655 Δ (L-Q), thus demonstrating the effectiveness of increasing CA production by reducing degradation and inhibition of RcsA.
4. To further increase CA production, key genes in the CA biosynthetic pathway galU and rcsA, in P20Overexpression was performed by a strong promoter, and a pRAU plasmid was constructed (FIG. 3). The method comprises the following specific steps:
(1) construction of pRAU plasmid
Use of the primer F-P20Amplification with P-rcsA-BamHI and R-rcsA-SacI (primer sequences shown in Table 2)20A strong promoter, Shine-Dalgarno (SD) sequence and an rcsA fragment of the cleavage site (BamHI and SacI)20The strong promoter sequence is: 5'-AATACTGATCATACTGTGATCATATATATATATAGCG-3', SD the sequence is: 5'-AAATCAGAGAGAGTATTGCTA-3' are provided.
Use of the primer F-P20Amplification of P-containing primers-galU-SacI and R-galU-XhoI (primer sequences shown in Table 2)20A galU fragment of a strong promoter, Shine-Dalgarno (SD) sequence and cleavage sites (SacI and XhoI), the above P20The strong promoter sequence is: 5'-AATACTGATCATACTGTGATCATATATATATATAGCG-3', SD the sequence is: 5'-AAATCAGAGAGAGTATTGCTA-3' are provided.
The rcsA fragment was digested with BamHI and SacI, galU with SacI and XhoI, vector pRSFDuet-1 with BamHI and XhoI, purified separately and then treated with T4The three DNA fragments were ligated by DNA ligase to construct a recombinant vector pRAU, which was verified by sequencing using the primers F-P20-rcsA-BamHI and R-galU-XhoI.
(2) Construction of WQM003/pRAU Strain
And (2) electrotransfering the pRAU plasmid prepared in the step (1) into the WQM003 strain prepared in the step (2) to prepare a WQM003/pRAU strain.
WQM003/pRAU was added to M9 medium and cultured at 30 ℃ and 200rpm for 48 hours, and the CA content in the fermentation broth was measured, and the results were: 1.58 g/L.
The CA production of WQM003/pRAU was increased 4.24-fold as compared with that of the original strain MG 1655. delta. (L-Q) (0.371 g/L).
5. Confirmation of extracellular polysaccharide (CA) production
In order to visually show the modification effect, the invention carries out exopolysaccharide tannin mordanting and exopolysaccharide (CA) dyeing at 30 ℃ and 37 ℃ so as to verify the synthesis of CA in M9, LB and LBG culture media at 30 ℃ and 37 ℃ (the result is shown in figure 4).
Extracellular polysaccharide (CA) of WQM003/pRAU was higher than MG 1655. delta. (L-Q) at 30 ℃ or 37 ℃ in M9 medium;
in LB medium, WQM003/pRAU also synthesized small amounts of exopolysaccharide (CA) at 30 ℃ or 37 ℃ while MG 1655. delta. (L-Q) did not synthesize exopolysaccharide CA.
In LBG medium, MG 1655. delta. (L-Q) and WQM003/pRAU synthesized extracellular polysaccharide at either 30 ℃ or 37 ℃, but it was clear that WQM003/pRAU synthesized more extracellular polysaccharide.
Overall, WQM003/pRAU synthesized more exopolysaccharides at different temperatures and in different media, and most strains formed more exopolysaccharides when cultured in M9 medium at 30 ℃.
Example 3: CA medium composition and fermentation condition optimization
1. Single factor experiment to optimize media composition
As can be seen from the results of exopolysaccharide staining in step 5 of example 2, the medium composition significantly affected exopolysaccharide production, and WQM003/pRAU produced the highest amount of exopolysaccharide when cultured at 30 ℃ in M9 medium compared with LB and LBG media. Therefore, medium optimization was performed in M9 medium. Investigating carbon source, nitrogen source and phosphoric acid by adopting single-factor test methodEffect of salt and NaCl on CA production to determine approximate variable ranges. Experiment by studying 4g/L glucose, 4g/L fructose, 4g/L galactose, 4g/L mannose and 4g/L sucrose, to select the best carbon source for CA biosynthesis; likewise, the optimum nitrogen source is selected from the group consisting of 10g/L NH4Cl, 10g/L peptone, 10g/L yeast extract and 1g/L corn steep liquor powder; wherein the glucose and KH2PO4、Na2HPO4·12H2O, NaCl can be varied in the range of 1-50 g/L, 3-9 g/L, 17.1-51.3 g/L and 0.5-1.5 g/L. In each single factor experiment, one factor was changed and the other factors were kept constant.
The method comprises the following specific steps:
(1) selection of carbon sources
Changing the carbon source in the M9 culture medium from glucose to fructose, galactose, mannose and sucrose respectively, with constant concentration and constant other components and content, inoculating WQM003/pRAU into culture medium containing different carbon sources, and culturing at 30 deg.C and 200rpm for 48h, with the results shown in FIG. 5A;
the carbon sources (glucose, fructose, galactose, mannose and sucrose) involved in CA biosynthesis were screened for CA production by WQM003/pRAU, and the results showed that CA production was highest in M9 medium when the carbon source was glucose (fig. 5A).
The optimal concentration of glucose was 20g/L as shown in FIG. 5B, when WQM003/pRAU was inoculated into glucose-containing media of different concentrations and cultured at 30 ℃ and 200rpm for 48 hours while changing the glucose concentration in M9 medium to 1g/L, 4g/L, 10g/L, 20g/L, 30g/L, 40g/L and 50g/L, respectively, and the other components and contents were not changed.
(2) Selection of Nitrogen Source
M9 minimal medium has no organic nitrogen source, so the CA mutant grown in M9 medium must synthesize some necessary substrates, which limits cell growth and increases incubation time.
Organic nitrogen sources (10g/L peptone, 10g/L yeast extract and 10g/L corn steep liquor powder) were respectively added directly to M9 medium and cultured at 30 ℃ and 200rpm for 48 hours, and the results are shown in FIG. 5C;
no matter what organic nitrogen source is added to the M9 medium, CA production is not favored. Therefore, NH is still employed4Cl was used as a nitrogen source, and the concentration was temporarily in accordance with that of M9 medium.
The RCS system is responsible for complex multistep phosphate cascade signaling, and the concentration of phosphate in the medium can significantly affect the regulation of the RCS system.
Respectively adding KH in M9 culture medium2PO4The concentrations of (A) were adjusted to 3g/L, 6g/L and 9g/L, and the other components and contents were unchanged, and it was found that the CA production gradually decreased with the increase in the concentration of potassium dihydrogen phosphate, and the optimum addition amount was 3g/L (FIG. 5D).
In KH2PO4Adjusting Na on the basis of the concentration of 3g/L2HPO4·12H2The O concentrations were 17.1g/L, 34.2g/L, 51.2g/L, and other components and contents were unchanged, and the results showed Na2HPO4·12H2The optimum concentration of O was 34.2g/L (FIG. 5E).
In KH2PO4The concentration is 3g/L, Na2HPO4·12H2On the basis that the O concentration is 34.2g/L, the NaCl concentrations are respectively adjusted as follows: 0.5g/L, 1.0g/L, and 1.5g/L, and other components and contents were unchanged, and the results showed that the optimum concentration of NaCl was 1.5g/L (FIG. 5F).
2. Plaket-Burman (PB) design for screening for significant changes in CA production
The experimental design scheme for PB is as follows:
the PB test design is an experimental method for screening out significant influence factors from a plurality of variables according to experimental results, and can estimate main factors as accurately as possible with the minimum number of tests. Minitab19.1 (64 bit) software was used for PB design and data processing. PB from 2 replicates and 24 runs of 7 components of M9 medium was designed to screen for major media components affecting CA production (tables 3-4).
TABLE 3 real values of variables in Plackett-Burman design
TABLE 4 Plackett-Burman design and yield of CA
The PB experimental design and regression analysis results are shown in fig. 6A and table 5. A (glucose) and C (Na)2HPO4·12H2O) is greater than the T limit in the normalized pareto chart (2.12) (FIG. 6A), A (glucose) and C (Na)2HPO4·12H2O) was less than 0.05 (table 5), from which it can be seen that these two factors have a significant effect on CA yield. The concentrations of the other 5 non-significant factors were averaged between the level (-1) and the level (+1), NH, in Table 34Cl(1g/L)、KH2PO4(3g/L)、NaCl(3g/L)、CaCl2(0.014g/L)、MgSO4(0.3 g/L). From the regression results, A (glucose) negatively affected CA production and C (Na)2HPO4·12H2O) had a positive effect on CA production (Table 5). This indicates that high concentrations of A (glucose) are detrimental to CA synthesis, while high concentrations of C (Na)2HPO4·12H2O) has a positive effect on the synthesis of CA. In addition, glucose and Na2HPO4·12H2The concentration of O will be optimized in the steepest hill climb and CCD experiments.
3. Steepest climbing experimental design
And designing a steepest climbing experiment according to the PB experiment result, and determining the central point of the central combination design. Glucose showed a negative effect, while Na2HPO4·12H2O showed a positive effect on CA production (table 5). Thus, the glucose concentration decreases with a fixed gradient, Na2HPO4·12H2The O concentration increases with a fixed gradient. The residual factor concentrations were determined from the PB experiments (Table 6), glucose and Na2HPO4·12H2Optimum of OThe concentration range was determined by the yield of CA.
Regression results for the PB design in Table 5
Significant at P values < 0.05; significant at P value <0.01
TABLE 6 experimental design and results of steepest ascent method
As shown in FIG. 6B, CA production increased gradually with increasing or decreasing concentration of the influencing factor. When the concentration of the glucose is 20g/L or 22g/L, Na2HPO4·12H2The CA production reached the highest value at an O concentration of 34g/L or 38 g/L. Subsequently, CA production decreased as the concentration of the influencing factor continued to change. Thus, the experiments were performed at an average concentration of glucose 21g/L and Na2HPO4·12H2O36 g/L was the center point to optimize the CCD experiment.
4. CCD optimization of glucose and Na2HPO4·12H2O concentration to maximize CA production
The response surface optimization method is a comprehensive mathematical and statistical method, and the influence of multiple factors on indexes is evaluated by using fewer experiments. As a response surface design, CCDs have been successfully applied in a multi-aspect optimization process. The invention uses glucose and Na2HPO4·12H2Two significant factors of O are independent variables and the levels of each factor are shown in table 7. Table 8 lists the experimental design of a CCD with two blocks. CCD design and data processing were performed using Minitab19.1 (64 bit) software.
TABLE 7 actual values of CCD arguments
TABLE 8 Experimental design and results of CCD vs. CA production
With glucose and Na2HPO4·12H2Two significant factors O are independent variables, the levels of the factors are shown in Table 7, and the experimental design and the results of the CCD are shown in Table 8; the model F value is 12.06, the P value is 0.002 (< 0.05), and the determinant coefficient (R2) is 0.9118, which indicates that the model item is significant; "mismatching F value" of 3.97 (> 0.05) means that mismatching errors are not significant relative to pure errors; therefore, the quadratic model fits well, resulting in the following regression equation:
Y=-19.80+1.344A+0.462C-0.03123A*A-0.00572C*C-0.00014A*C。
the 2D and 3D response surface plots were plotted based on the regression equation (fig. 6C). Glucose and Na2HPO4·12H2The cross contour plot of O is approximately circular, and CA production is a function of glucose and Na2HPO4·12H2The increase in O concentration increases first and then decreases; glucose and Na2HPO4·12H2P value for O interaction was 0.974, greater than 0.05, interaction was not significant (table 9); response surface results were consistent with analysis of variance (ANOVA) results; maximizing CA production was predicted by the response optimizer of Minitabb 19.1; when glucose and Na2HPO4·12H2The predicted yield of CA was highest (12.52g/L) at O levels of 21.47g/L and 40.2g/L, respectively; the final optimized medium for CA production was 21.47g/L glucose, 1g/L NH4Cl,40.2g/L Na2HPO4·12H2O,3g/L KH2PO4,3g/L NaCl,0.014g/L CaCl2,0.24g/L MgSO4。
The optimized medium was used to verify its effectiveness for CA production. The CA yield measured by the experiment is 12.47g/L, which is equivalent to the statistical predicted value of 12.52g/L, and the error range is 0.17 g/L; this demonstrates the effectiveness and accuracy of the CA media after CCD optimization. To date, CA production was 33.58-fold increased compared to E.coli MG 1655. delta. (L-Q) production (0.371g/L) without metabolic engineering and media optimization.
TABLE 9 CCD regression results analysis
*R2=0.9122
According to the steps 1-4, the optimized culture medium formula is as follows: 15-30 g/L glucose, 35-45 g/L Na2HPO4·12H2O,1~8g/L NH4Cl,2~4g/L KH2PO4,2~4g/L NaCl,0.01~0.05g/L CaCl2And 0.1-0.5 g/L MgSO4。
Wherein the optimal culture medium is 21.47g/L glucose and 1g/L NH4Cl,40.2g/L Na2HPO4·12H2O,3g/L KH2PO4,3g/L NaCl,0.014g/L CaCl2,0.24g/L MgSO4。
5. Optimization of 2.0L fermentation tank submerged fermentation process
The submerged fermentation process was optimized in a 2.0L fermentor.
The seed culture medium involved in the step is as follows: LB culture medium;
the fermentation medium is as follows: 21.47g/L glucose, 1g/L NH4Cl,40.2g/L Na2HPO4·12H2O,3g/L KH2PO4,3g/L NaCl,0.014g/L CaCl2,0.24g/L MgSO4。
(1) Optimization of inoculum size
The WQM003/pRAU strain prepared in example 2 was inoculated into the seed medium and cultured at 37 ℃ and 200rpm for 12 hours to prepare a seed solution;
respectively preparing the seed liquid according to OD600Inoculating the strain into a fermentation culture medium according to the proportion of 0.02, 0.08, 0.14 and 0.2, culturing for 72 hours at the temperature of 30 ℃ and the pH value of 7, starting dissolved oxygen automatic control, controlling the dissolved oxygen level to be not less than 30%, and respectively detecting the content of CA in a culture solution after the fermentation is finished, wherein the results are respectively as follows: 12.55g/L, 13.79g/L, 9.57g/L and 7.51 g/L.
(2) Optimization of pH
Respectively using the seed liquid prepared in the step (1) according to OD600Inoculating the strain into a fermentation medium according to the proportion of 0.08, culturing for 72 hours at the temperature of 30 ℃ under the conditions that the pH value is 6.0-7.0 and the pH value is not controlled, starting a dissolved oxygen self-control mode, keeping the dissolved oxygen level to be not lower than 30%, and respectively detecting the content of CA in a culture solution after the fermentation is finished, wherein the results are respectively as follows: 19.79g/L and 14.09 g/L.
The inoculum size and pH of the CA fermentations were tested in a four-way fermentor based on the optimal fermentation medium. The optimum inoculum size was 0.08 (FIG. 6D), and the pH was not lower than 6.0 (FIGS. 6E and 6F).
The results show that optimization of the fermentor greatly increased the yield of CA to 19.79 g/L.
The reason is that: on one hand, the viscosity of the fermentation liquid is increased (CA accumulation) to cause that the dissolved oxygen in the shake flask fermentation is low in the later period of the shake flask fermentation, so that the growth of low dissolved oxygen strains cannot be met, and the CA yield is low. When the culture medium is cultured in a fermentation tank, the problem of insufficient dissolved oxygen caused by viscosity rise is solved at high rotating speed, and the culture medium is more favorable for cell growth and CA production; on the other hand, the pH needs to be kept at 6.0 during CA fermentation, under which conditions glucose can be completely consumed and completely converted to CA. Otherwise, the pH at the end of the fermentation may drop to 5.4, while glucose is still present, resulting in low CA production.
In conclusion, the invention enables the CA yield to reach 19.79g/L and the conversion rate to reach 92 percent by a series of effective measures such as constructing a mutant strain with high CA yield, optimizing a culture medium, optimizing a fermentation process and the like, and the CA yield is improved by 53.25 times compared with the CA yield (0.37g/L) of the original strain MG1655 delta (L-Q). The CA yields of the present invention are currently the highest compared to the known literature.
Example 4: CA characterization
1. Identification, structural and thermal Properties of CA
After the CA supernatant is purified and freeze-dried, a CA solid sample of 18.18 +/-0.57 g/L is obtained, and the recovery rate is 91.86 +/-2.88%. Upon visual inspection, the lyophilized CA resembled a napkin shred (FIG. 7A). SEM observations showed that the CA solid samples aggregated into bundles (wires) and existed in filamentous or broad fiber shapes (fig. 7B).
It is reported that CA is composed of repeating polymeric units consisting of D-galactose, L-fucose, D-gluconic acid and D-glucose. To verify that the purified polymer of the present invention is indeed CA, the monosaccharide composition of the polymer was examined. As shown in fig. 5C, the purified polymer is composed of four monosaccharides, all of which are strongly correlated with the composition of CA. Furthermore, the average MW of CA is about 485X 106Daltons (fig. 7D), much larger than most reported exopolysaccharides.
In addition, the present invention also analyzes the high-level structure of CA. Congo red is an acidic high molecular dye, and can form a stable complex with polysaccharide with triple helix conformation under the action of strong hydrogen bond or hydrophobic effect under the action of sodium hydroxide with a certain concentration, then the maximum absorption wavelength of the complex moves to long wavelength, and when the concentration of the sodium hydroxide is continuously increased, the hydrogen bond between molecules is broken, and the maximum absorption wavelength is rapidly reduced. As shown in FIG. 8A, the maximum absorption wavelength increased at a sodium hydroxide concentration of 0-0.05mol/L, indicating that CA can form a complex with Congo red and has a triple helix conformation. Then, the maximum absorption wavelength sharply decreased with the increase of the NaOH concentration, indicating that the CA helix structure was broken down into single strands, failed to form a complex with congo red, and became an irregular helix group form. Briefly, CA was initially judged to have an ordered triple-helical conformation.
In addition, the high-level structure was further explored using circular dichroism spectroscopy (fig. 8B). It can be seen that the negative effects of CA in aqueous solution at 200-221nm indicate that CA has chiral and triple helical conformation in aqueous solution. The triple helix conformation of CA was analyzed by dichroweb to be 15.15 ± 0.15%. The triple helix conformation is usually biologically active and the pharmacological activity of CA is therefore to be studied further. In addition, different chain conformations of polysaccharides in solution often exhibit different biological activities. The chain conformation of CA in aqueous solution was further investigated by atomic force microscopy and dynamic light scattering. As shown in the atomic force microscope image (fig. 8C), CA exhibited a spherical chain conformation in an aqueous solution, and the average particle diameter was 286.44 nm. The dynamic light scattering results showed that the average particle size of CA in the aqueous solution was 0.094nm and 222.7nm, accounting for 0.13% and 99.87%, respectively (fig. 8D). The average particle size of 0.094nm may be due to the single-stranded triple-helix conformation of a small amount of CA present in aqueous solution.
Thermal analysis is widely used to characterize the thermal, physical and stability properties of materials and is very important for quality control in material development and production. In this study, DSC was performed to reveal the thermal properties of CA (fig. 8E). The heat flux does not change much from 30 ℃ to 102 ℃, indicating that the CA is in a solid-solid transition or bound water loss stage. When CA is continuously heated, the heat flux curve rises, the CA generates glass transition, which shows that the CA structure is changed, and the glass transition temperature Tg is 123.52 ℃. With increasing temperature, the heat flux curve shows an endothermic peak, when the energy gained in the CA molecule is too much to maintain an ordered structure, the CA begins to melt, and the melting temperature Tm is 253.89 ℃. When the temperature was raised to 291.94 ℃, an endothermic peak appeared and CA began to decompose and gasify.
2. Rheological Properties of CA
CA is a natural high molecular polymer whose viscosity and associated rheological properties can have a significant impact on the development, stability, and design and selection of process equipment for new products. The rheological properties of carbohydrate polymers are influenced by a number of factors. In this study, the rheological properties of CA were studied.
FIG. 7A shows the effect of CA concentration on viscosity at 25 ℃. In 1 to 1000s-1Within the shear rate range, the viscosity increases with increasing CA concentration. As the shear rate increases, the viscosity of the CA gradually decreases, indicating the shear-thinning flow behavior of the non-Newtonian fluid. The viscosity of the CA solutions of different concentrations gradually decreased, showing the shear thinning behavior of the non-Newtonian fluid. The viscosity curves of CA were fitted by Carreau modelWherein eta is the shear viscosity of the polymer,is the shear rate, λ is the relaxation time, η∞Is the ultimate shear viscosity, η0Is zero shear viscosity, n is the pseudoplasticity index, pseudoThe n-value of the plastic fluid is between 0 and 1 (spark J, Holland C. analysis of the pressure requirements for a bulk lubricating treated process J]Nature Communications, 2017.8.). Carreau model parameters are shown in Table 10, CA aqueous solution 0<n<1 is presumed to be a pseudoplastic fluid. Further, as the CA concentration increases, λ and η0The higher the value, the lower the value of n, indicating that the higher the CA concentration, the higher the shear-thinning ability. This is probably because the orientation of the polymer molecular chains tends to converge with an increase in the shear rate, resulting in a decrease in the solution viscosity. Similar results have been reported (Xu J L, Zhang J C, Liu Y, et al, Rheological properties of a polysaccharide from flow polysaccharides in Huanggshan mountain [ J].Carbohydrate Polymers,2016.139:43-49.)。
TABLE 10 fitting parameters of Carreau model
Fig. 9B reveals the effect of temperature on the rheological properties of CA. The viscosity of the CA decreases rapidly with increasing temperature and the solution viscosity decreases more with increasing CA concentration. This may be due to reduced intermolecular interactions and reduced flow resistance. Therefore, the viscosity of CA can be reduced by properly increasing the temperature in industrial production, thereby effectively reducing the energy consumption of liquid pipeline transportation. Fig. 9C investigates the effect of pH on CA rheology, with CA viscosity being highest in a neutral environment (pH 7.0), and acidic or basic solutions decreasing CA viscosity. This is probably due to a change in electrostatic repulsion of the CA molecules, resulting in a conformational transition of CA with a corresponding decrease in viscosity. Therefore, the effect of pH on its viscosity and stability should be considered in CA applications. Figure 9D shows the effect of salt ion on CA rheology. The viscosity of the CA solution is dependent on NaCl, KCl, CaCl2And MgCl2Slightly increased and as the salt solution concentration increased, there was little change in the viscosity of the CA. The results show that CA has good tolerance to salt ions.
Studying the viscoelastic effect of polysaccharide solutions to determine whether the solution is viscous or elastic under given conditions can effectively control the viscoelastic effect of the solution in polysaccharide production and application. The viscoelastic strength of the polysaccharide solution can be reflected by the storage modulus G' and the loss modulus G ″. G 'may reflect the solid-like nature of the viscoelastic material and G' may reflect the liquid-like nature of the viscoelastic material. The loss factor tan δ G ″/G' more intuitively reflects the dynamic viscoelastic characteristics of the fluid. When tan δ >1, the sample is shown to behave as a viscous liquid; conversely, the sample tends to behave more as an elastic solid.
As shown in fig. 10, both the storage modulus and loss modulus of the CA solution increased with increasing CA concentration. When the CA concentration was 20G/L, G 'was always greater than G', tan. delta. >1, the CA solution was fluid (FIG. 10A); when the angular frequency was less than 1.98rad/s, G "> G', tan. delta. >1, 40G/L (FIG. 10B), 60G/L (FIG. 10C) and 80G/L of CA solution L (FIG. 10D) exhibited mainly gel characteristics. As the angular frequency continues to rise, G '< G', tan delta < 1, viscoelastic fluid properties are exhibited. When the CA concentrations were 40G/L, 60G/L, and 80G/L, respectively, G "and G" crossed, and the angular frequencies at the crossing points were 1.98rad/s, 8.02rad/s, and 29.7rad/s, respectively. This is probably due to the fact that the smaller the angular frequency, the longer the requirements on vibrational shear, and the more time the macromolecule has to change conformation, get rid of entanglement, and overtake each other. At this time, the elastic extension of the branched chain can be gradually recovered in the flow, so that the viscosity of the solution is dominant, and the elasticity is not significant. Although the angular frequency is high and the vibration shearing force action time is short, the elastic deformation energy is mostly stored in the system, so the elasticity is dominant.
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (10)
1. A recombinant Escherichia coli, wherein the recombinant Escherichia coli is characterized in that a lipopolysaccharide core polysaccharide synthesis gene cluster waaL, waaU, waaZ, waaY, waaR, waaO, waaB, waaP, waaG and waaQ on a genome are knocked out, Escherichia coli with a Lon protein coding gene Lon and an HNS regulatory protein coding gene HNS knocked out is taken as a host cell, and a UTP-1-phosphoglucose uridyltransferase coding gene galU and a DNA binding transcription activator RcsA coding gene rcsA are overexpressed.
2. The recombinant escherichia coli of claim 1, wherein the NCBI accession numbers of the lipopolysaccharide core polysaccharide synthesis gene clusters waaL, waaU, waaZ, waaY, waaR, waaO, waaB, waaP, waaG, waaQ are, in order, 948148, 948147, 948146, 948145, 948142, 948143, 948144, 948150, 948149, 948155; the NCBI accession number for lon is 945085; the NCBI accession number of hns is 945829; the NCBI accession number of galU is 945730; the NCBI accession number for rcsA is 946467.
3. The recombinant Escherichia coli of claim 1 or 2, wherein the recombinant Escherichia coli has Escherichia coli str K-12MG1655 as a host cell.
4. The recombinant Escherichia coli of any one of claims 1 to 3, wherein pRSFDuet-1 is used as an expression vector.
5. A method for producing clavulanic acid by glucose fermentation is characterized by comprising the following steps: the recombinant Escherichia coli is prepared by fermentation of the recombinant Escherichia coli of any one of claims 1 to 4.
6. The method of claim 5, wherein the seed solution of the recombinant Escherichia coli is inoculated into a fermentation medium and fermented to produce clavulanic acid; wherein the fermentation medium comprises: 15-30 g/L glucose, 35-45 g/L Na2HPO4·12H2O,1~8g/L NH4Cl,2~4g/L KH2PO4,2~4g/L NaCl,0.01~0.05g/L CaCl2And 0.1-0.5 g/L MgSO4。
7. The method of claim 5 or 6, wherein the recombinant E.coli seed solution is inoculated in the fermentation medium at OD6000.04 to 0.21.
8. The method according to any one of claims 5 to 7, wherein the seed solution of the recombinant Escherichia coli is inoculated into a fermentation medium under the following conditions: at 25-37 deg.C and 150-250 rpm.
9. Claritanic acid prepared by the process of any one of claims 5 to 8.
10. Use of the recombinant Escherichia coli of any one of claims 1 to 4 in the preparation of a product containing clavulanic acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111151501.6A CN113755515B (en) | 2021-09-29 | 2021-09-29 | Recombinant escherichia coli for efficiently producing clavulanic acid and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111151501.6A CN113755515B (en) | 2021-09-29 | 2021-09-29 | Recombinant escherichia coli for efficiently producing clavulanic acid and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113755515A true CN113755515A (en) | 2021-12-07 |
CN113755515B CN113755515B (en) | 2023-10-03 |
Family
ID=78798183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111151501.6A Active CN113755515B (en) | 2021-09-29 | 2021-09-29 | Recombinant escherichia coli for efficiently producing clavulanic acid and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113755515B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114908031A (en) * | 2022-06-23 | 2022-08-16 | 江南大学 | Construction of escherichia coli strain with truncated lipopolysaccharide structure for efficiently producing clavulanic acid |
CN115287314A (en) * | 2022-09-15 | 2022-11-04 | 深圳柏垠生物科技有限公司 | Kola acid fermentation amplification process |
CN115466724A (en) * | 2022-10-21 | 2022-12-13 | 唐颐控股(深圳)有限公司 | Screening method and application of optimal factor value in human mesenchymal stem cell amplification |
WO2024141022A1 (en) * | 2022-12-30 | 2024-07-04 | 深圳柏垠生物科技有限公司 | Construction and use of engineering bacterium that produces colanic acid with high yield |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109439708A (en) * | 2018-11-15 | 2019-03-08 | 中国科学院上海高等研究院 | A kind of method that the Escherichia coli production of acid resistant form high-density growth can draw acid |
-
2021
- 2021-09-29 CN CN202111151501.6A patent/CN113755515B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109439708A (en) * | 2018-11-15 | 2019-03-08 | 中国科学院上海高等研究院 | A kind of method that the Escherichia coli production of acid resistant form high-density growth can draw acid |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114908031A (en) * | 2022-06-23 | 2022-08-16 | 江南大学 | Construction of escherichia coli strain with truncated lipopolysaccharide structure for efficiently producing clavulanic acid |
CN114908031B (en) * | 2022-06-23 | 2023-07-25 | 江南大学 | Construction of lipopolysaccharide-structured truncated E.coli strain for efficiently producing clavulanic acid |
CN115287314A (en) * | 2022-09-15 | 2022-11-04 | 深圳柏垠生物科技有限公司 | Kola acid fermentation amplification process |
CN115466724A (en) * | 2022-10-21 | 2022-12-13 | 唐颐控股(深圳)有限公司 | Screening method and application of optimal factor value in human mesenchymal stem cell amplification |
WO2024141022A1 (en) * | 2022-12-30 | 2024-07-04 | 深圳柏垠生物科技有限公司 | Construction and use of engineering bacterium that produces colanic acid with high yield |
Also Published As
Publication number | Publication date |
---|---|
CN113755515B (en) | 2023-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113755515B (en) | Recombinant escherichia coli for efficiently producing clavulanic acid and application thereof | |
JP3062459B2 (en) | Polyester synthase gene and method for producing polyester | |
KR101357015B1 (en) | Recombinant microorganisms for increased production of organic acids | |
EP2443228B1 (en) | Zymomonas with improved arabinose utilization | |
WO2010037119A1 (en) | Enhanced iron-sulfur cluster formation for increased dihydroxy-acid dehydratase activity in lactic acid bacteria | |
WO2007144018A1 (en) | Ethanolamine production by fermentation | |
HUE025564T2 (en) | Improved xylose utilization in recombinant zymomonas having increased ribose-5-phosphate activity | |
JP2013545491A (en) | Enhancement of ethanol production by xylose-utilizing zymomonas mobilis in biomass hydrolyzate medium | |
CN107771214A (en) | For with the microorganism modified caused by 2,4 dihydroxy butyric acid of the optimization of row's thing outside increased 2,4 dihydroxy butyric acid | |
CN112941052B (en) | Chitosanase OUC-T613 and application thereof | |
CN111748535B (en) | Alanine dehydrogenase mutant and application thereof in fermentation production of L-alanine | |
JP2013537429A (en) | Improved glycolic acid fermentation production by modified microorganisms | |
BRPI0721283B1 (en) | HOST CELL, METHODS FOR PRODUCING A POLYPEPTIDE AND FOR PRODUCING BIOETHANOL AND USE OF A POLYPEPTIDE, NUCLEIC ACID MOLECULE OR HOST CELL | |
Salgado et al. | Missense mutations in a transmembrane domain of the Komagataeibacter xylinus BcsA lead to changes in cellulose synthesis | |
CN110144341B (en) | Alginate lyase mutant | |
JP6109190B2 (en) | PNP gene modification for improved xylose utilization in Zymomonas | |
JPH10276781A (en) | Polyester polymerization enzyme and gene encoding the same | |
CN114908031B (en) | Construction of lipopolysaccharide-structured truncated E.coli strain for efficiently producing clavulanic acid | |
CN111979167B (en) | Recombinant clostridium butyricum for efficiently converting straw biomass carbon source and construction method and application thereof | |
CN110804602B (en) | L-aspartic acid beta-decarboxylase mutant and application thereof | |
CN114410562A (en) | Klebsiella engineered bacterium and application thereof in ethanol production | |
CN109486793B (en) | Sucrose hydrolase mutant and preparation method and application thereof | |
EP2995684B1 (en) | Recombinant microorganism metabolizing 3,6-anhydride-l-galactose and a use thereof | |
CN112695051B (en) | Genetically engineered bacterium for producing ethanol by using xylose and construction method and application thereof | |
KR101432072B1 (en) | Strains expressing FrsA protein and methods of producing ethanol using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |